AVIA Vascular

Executive Summary

AVIA Vascular is a US-based medical device company addressing the clinical challenge of venous depletion caused by frequent venipuncture. Its proprietary device, The Ally, enables needle-free blood draws for inpatients, preserving vasculature and improving patient outcomes. By reducing needle use, the technology aims to lower complication rates, enhance patient comfort, and reduce healthcare costs associated with repeated venous access. Founded in 2019 and headquartered in San Jose, California, the company operates in the cardiovascular and medical device sectors. Although still private with limited public financial data, AVIA Vascular's innovative approach targets a significant unmet need in hospital settings where patients often require multiple blood draws. The company's focus on needle-free technology aligns with broader trends toward minimally invasive procedures and improved patient safety. With a strong value proposition for hospitals seeking to reduce costs and improve care, AVIA Vascular is positioned for growth pending regulatory milestones and commercial adoption.

Upcoming Catalysts (preview)

• Q4 2025FDA 510(k) Clearance for The Ally75% success
• Q2 2026Clinical Study Results Demonstrating Efficacy60% success
• Q3 2026Strategic Partnership with Hospital Network50% success